By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Wyeth v. Cadila Healthcare Ltd. et al.
1:09-cv-00239; filed April 9, 2009 in the District Court of Delaware
Infringement of U.S. Patent Nos. 6,274,171 ("Extended release formulation of venlafaxine hydrochloride," issued August 14, 2001), 6,403,120 (same title, issued June 11, 2002), and 6,419,958 (same title, issued July 16, 2002) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Wyeth's EFFEXOR XR® (venlafaxine hydrochloride, extended release, used to treat depression). View the complaint here.
Allergan, Inc. v. Sandoz Inc
2:09-cv-00097; filed April 7, 2009 in the Eastern District of Texas
Infringement of U.S. Patent Nos. 7,030,149 ("Combination of Brimonidine Timolol For Topical Ophthalmic Use," issued April 18, 2006) and 7,320,976 (same title, issued January 22, 2008) following a Paragraph IV certification as part of Sanoz's filing of an ANDA to manufacture a generic version of Allergan's Combigan® (brimonidine tartrate/timolol maleate ophthalmic solution, used to treat glaucoma). View the complaint here.
Abbott Laboratories et al. v. Sandoz, Inc. et al.
3:09-cv-01587; filed April 2, 2009 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,246,925 ("19-nor-Vitamin D Compounds for Use in Treating Hyperparathyroidism," issued September 21, 1993), 5,587,497 ("19-nor-Vitamin D Compounds," issued December 24, 1996), 6,136,799 ("Cosolvent Formulations," issued October 24, 2000), and 6,361,758 (same title, issued March 26, 2002) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Abbott's Zemplar® (paricalcitol, used to treat secondary hyperparathyroidism in patients with kidney failure). View the complaint here.
Comments